

Andrew D Simmons

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/514374/publications.pdf>

Version: 2024-02-01

23
papers

2,054
citations

840776

11
h-index

752698

20
g-index

23
all docs

23
docs citations

23
times ranked

3806
citing authors

#	ARTICLE	IF	CITATIONS
1	Population pharmacokinetics of rucaparib in patients with advanced ovarian cancer or other solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 89, 671-682.	2.3	7
2	Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 3651-3667.	6.4	57
3	Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms. <i>Clinical Cancer Research</i> , 2021, 27, 3094-3105.	7.0	101
4	Genomic analysis of circulating tumor DNA in 3,334 patients with advanced prostate cancer to identify targetable BRCA alterations and AR resistance mechanisms.. <i>Journal of Clinical Oncology</i> , 2021, 39, 25-25.	1.6	2
5	Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2. <i>Gynecologic Oncology</i> , 2021, 161, 668-675.	1.4	7
6	Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 Study. <i>Clinical Cancer Research</i> , 2021, 27, 6677-6686.	7.0	12
7	Genomic Profiles of De Novo High- and Low-Volume Metastatic Prostate Cancer: Results From a 2-Stage Feasibility and Prevalence Study in the STAMPEDE Trial. <i>JCO Precision Oncology</i> , 2020, 4, 882-897.	3.0	22
8	Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a <i>BRCA1</i> or <i>BRCA2</i> Gene Alteration. <i>Journal of Clinical Oncology</i> , 2020, 38, 3763-3772.	1.6	448
9	Polyclonal BRCA2 mutations following carboplatin treatment confer resistance to the PARP inhibitor rucaparib in a patient with mCRPC: a case report. <i>BMC Cancer</i> , 2020, 20, 215.	2.6	30
10	Evaluation of <i>in vitro</i> absorption, distribution, metabolism, and excretion and assessment of drug-drug interaction of rucaparib, an orally potent poly(ADP-ribose) polymerase inhibitor. <i>Xenobiotica</i> , 2020, 50, 1032-1042.	1.1	25
11	Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study. <i>Clinical Cancer Research</i> , 2020, 26, 2487-2496.	7.0	273
12	Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer. <i>Nature Medicine</i> , 2019, 25, 111-118.	30.7	196
13	Targeted next-generation sequencing (tNGS) of metastatic castrate-sensitive prostate cancer (M1) Tj ETQq1 1 0.784314 rgBT /Overl <i>Oncology</i> , 2019, 37, 5019-5019.	1.6	7
14	Genomic characteristics of deleterious BRCA1 and BRCA2 alterations and associations with baseline clinical factors in patients with metastatic castration-resistant prostate cancer (mCRPC) enrolled in TRITON2.. <i>Journal of Clinical Oncology</i> , 2019, 37, 5031-5031.	1.6	4
15	ATLAS: A phase II open-label study of rucaparib in patients with locally advanced or metastatic urothelial carcinoma (mUC).. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS496-TPS496.	1.6	2
16	TRITON2: An international, multicenter, open-label, phase II study of the PARP inhibitor rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD).. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS388-TPS388.	1.6	11
17	TRITON3: An international, randomized, open-label, phase III study of the PARP inhibitor rucaparib vs. physician's choice of therapy for patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD).. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS389-TPS389.	1.6	17
18	Response to platinum-based therapy (PBT) and immune checkpoint inhibitors (ICI) in metastatic urothelial carcinoma (mUC) patients (pts) with genomic alterations (GA) in homologous recombination repair (HRR) genes.. <i>Journal of Clinical Oncology</i> , 2018, 36, 447-447.	1.6	0

#	ARTICLE	IF	CITATIONS
19	ATLAS: A phase 2, open-label study of rucaparib in patients (pts) with locally advanced or metastatic urothelial carcinoma (mUC).. Journal of Clinical Oncology, 2018, 36, TPS4592-TPS4592.	1.6	1
20	Efficacy and immune modulation of the tumor microenvironment with the combination of the PARP inhibitor rucaparib and CD122-biased agonist NKTR-214.. Journal of Clinical Oncology, 2018, 36, 5582-5582.	1.6	0
21	Secondary Somatic Mutations Restoring <i>RAD51C</i> and <i>RAD51D</i> Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. Cancer Discovery, 2017, 7, 984-998.	9.4	310
22	Trial of rucaparib in prostate indications 3 (TRITON3): An international, multicenter, randomized, open-label phase 3 study of rucaparib vs physician's choice of therapy for patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD).. Journal of Clinical Oncology, 2017, 35, TPS5087-TPS5087.	1.6	2
23	Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. Nature Communications, 2016, 7, 11815.	12.8	520